Who Paid My Doc
Laura Ferguson-Weigman
Nurse Practitioner, Primary Care Bel Air, MD Nurse Practitioner
NPI 1306244769 CMS profile 11034502
500 Upper Chesapeake Dr, Bel Air, MD 21014
General payments
$5,119
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Laura Ferguson-Weigman of Bel Air, MD is reported in the CMS Open Payments database as having received $5,119 across 276 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,369 | 66 | |
| 2024 | General | $1,449 | 75 | |
| 2023 | General | $1,903 | 113 | |
| 2022 | General | $397 | 22 |
Beside peers
- Laura Ferguson-Weigman
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Laura Ferguson-Weigman were reported at $1,369. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Laura Ferguson-Weigman | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $137 | $39–$445 | $132 |
| 2022 | $397 | $139 | $44–$421 | $149 |
| 2023 | $1,903 | $163 | $53–$481 | $160 |
| 2024 | $1,449 | $176 | $54–$511 | $164 |
| 2025 | $1,369 | $169 | $51–$499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 26 drugsPart D claims
647
Drug cost
$22,511
Branded share of claims
7.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | Brand | 11 | $15,563 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 17 | $880 | |
| Losartan Potassium | Generic | 56 | $573 | |
| Rosuvastatin Calcium | Generic | 29 | $506 | |
| Atorvastatin Calcium | Generic | 62 | $504 | |
| Levothyroxine Sodium | Generic | 39 | $413 | |
| Metoprolol Succinate | Generic | 38 | $401 | |
| Bupropion Xl Bupropion Hcl | Brand | 18 | $388 | |
| Lisinopril | Generic | 40 | $340 | |
| Pravastatin Sodium | Generic | 19 | $322 |
The 10 drugs with the highest cost, of 26 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 33 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| FARXIGA |
|
$127 | 11 | — |
| RYBELSUS |
|
$83 | — | — |
| Ozempic |
|
$83 | — | — |
| TRELEGY ELLIPTA |
|
$73 | — | — |
| Otezla |
|
$72 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 33 with PatronRecords
276 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Primary Care in Maryland
Ashley Salamone
Nurse Practitioner, Primary Care · Baltimore, MD
Ololade Ikuomola
Nurse Practitioner, Primary Care · Baltimore, MD
Patricia Goodman
Nurse Practitioner, Primary Care · Uppr Marlboro, MD
Jody Leonard
Nurse Practitioner, Primary Care · Annapolis, MD
Yury Malachevsky
Nurse Practitioner, Primary Care · Baltimore, MD
Kyleen Davis
Nurse Practitioner, Primary Care · Chevy Chase, MD
Related records
Nurse Practitioner, Primary Care in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.